← Back to patent-cliff list
拉坦前列素
Tier C — Watch / tradeLatanoprost
辉瑞
Originator
1996
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：PTGFR
Brand：MicroProst、适利达、Latoprost、Xelpros、Monoprost、Catioprost、Xalatan、Eye-D
Indications (approved)：高眼压、开角型青光眼
Regional status
US
批准上市
1996-06-05
EU
批准上市
2023-11-15
China
批准上市
1999-02-13
Japan
批准上市
1999-03-12
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Latanoprost?
Approved indications include: 高眼压, 开角型青光眼.
When does the Latanoprost patent expire?
No public expiry year is available for Latanoprost yet; this page updates once verified.
How do I get a quote for Latanoprost intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25